Cervical Intraepithelial Neoplasia
Conditions
Keywords
cervical intraepithelial neoplasia (CIN), progesterone
Brief summary
The investigators want to test whether treatment with a natural progesterone intravaginally increases the cure rate of cervical intraepithelial neoplasia grade I and II.
Detailed description
Background: 1. The development of cervical intraepithelial neoplasia (CIN) was linked to a decreased local immune response as evidenced by a decrease of Langerhans' cell (LC) count in the cervical epithelium. Preliminary studies show that vaginally administered progesterone locally increases the number of LCs. 2. There is no accepted treatment strategy of low grade CIN, i.e., CIN I and II, than await spontaneous regression. Thus, vaginal progesterone is expected to increase the regression rate of cervical dysplasia grade I and II. Outcome parameters: Primary outcome parameters: To evaluate whether or not a treatment with vaginal progesterone increases regression and remission rates of CIN I and II during a 6-month treatment period. Secondary outcome parameters: Change of immunohistochemically detected expression of LCs in CIN. Methods: Prospective phase II trial with vaginal progesterone as treatment of CIN I and II. 60 patients receive vaginal micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25 for 6 months. After 3 and 6 months patients are examined for possible regression, persistence, or progression of disease and treated accordingly. Treatment of patients with progressing CIN is being discontinued after 3 months. Follow-up of patients is ensured based on current clinical practice, i.e., regular outpatient visits every 3 months, until the lesion completely regresses. Diagnosis and main inclusion criteria: CIN I and II diagnosed by punch biopsy, lesion fully visible, otherwise healthy subjects \< 60 years, no history of breast cancer, patient's compliance Medication: Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25 Duration of treatment: 6 months
Interventions
DRUGprogesterone
Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25
Sponsors
Medical University of Vienna
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Histological evidence of CIN I and II 2. Transformation zone and lesion margins fully visible 3. Compliant subject 4. Safe contraception 5. Negative pregnancy test
Exclusion criteria
Lesion related 1. CIN III, (micro)-Invasive Cancer 2. Endocervical lesion, upper margin of lesion not visible on colposcopy 3. Non-compliance of patient 4. PAP V Drug related 1. Age \> 60 2. Hypersensitivity to progesterone or any component of the formulation 3. Thrombophlebitis 4. Undiagnosed vaginal bleeding 5. Carcinoma of the breast 6. Cerebral apoplexy 7. Severe liver dysfunction 8. Pregnancy 9. Depression 10. Diabetes 11. Epilepsy 12. Migraine 13. Renal dysfunction 14. Asthma 15. HIV infection 16. Hepatitis B or C 17. Concurrent use of anticoagulants 18. Uncontrolled hypertension (\> 160/90 mmHg) 19. Breast cancer in personal history 20. Concurrent hormonal therapy including OC Clinical laboratory related 1. Hemoglobin \< 11 g/dl 2. Leukocytes \< 4,0 x 109/L 3. Platelet count \< 100 x 109/L 4. Serum bilirubin \> 2 x above upper cut-off value 5. Serum GOT \> 2 x above upper cut-off value 6. Serum GPT \> 2 x above upper cut-off value 7. Serum alkaline phosphatase \> 2 x above upper cut-off value 8. Serum creatinine \> 2 x above cut-off value
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate whether or not a treatment with vaginal progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25 for 6 months increases regression rates of CIN I and II. | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Change of immunohistochemically detected expression of Langerhans Cells in CIN | 6 months |
Countries
Austria
Outcome results
None listed